Page last updated: 2024-11-08

amiridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

amiridine: do not confuse with neuromedin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID604519
CHEMBL ID130880
CHEBI ID125612
SCHEMBL ID28251
MeSH IDM0142663

Synonyms (58)

Synonym
HMS1685B19
HMS3393C11
2,3,5,6,7,8-hexahydro-1h-cyclopenta[b]quinolin-9-ylamine
amiridine
brn 0475930
1h-cyclopenta(b)quinolin-9-amine, 2,3,5,6,7,8-hexahydro-
9-amino-2,3,5,6,7,8-hexahydro-1h-cyclopenta(b)quinoline
2,3,5,6,7,8-hexahydro-1h-cyclopenta(b)quinolin-9-amine
OPREA1_388798
OPREA1_177774
CBDIVE_008152
MLS001423960
MLS000758231
smr000449322
1h-cyclopenta[b]quinolin-9-amine, 2,3,5,6,7,8-hexahydro-, monohydrochloride- [cas]
ipidacrine
cpd000449322
2,3,5,6,7,8-hexahydro-1h-cyclopenta[b]quinolin-9-amine
CHEBI:125612
HMS2051C11
CHEMBL130880 ,
62732-44-9
1h,2h,3h,5h,6h,7h,8h-cyclopenta[b]quinolin-9-amine
F6170-0039
bdbm50279987
AKOS000663960
BBL003609
9-amino-2,3,5,6,7,8-hexahydro-1h-cyclopenta[b]quinoline
STK520619
HMS2232L05
CCG-100784
cv71vtp0vn ,
ipidacrine [inn]
unii-cv71vtp0vn
FT-0601640
ipidacrine [mi]
ipidacrine [who-dd]
ipidacrine [mart.]
NC00034
SCHEMBL28251
MB01346
DTXSID7048299
9-amino-2,3,5,6,7,8-hexahydro-1h-cyclopent[b]quinoline
1h-cyclopenta(b)quinoline, 2,3,5,6,7,8-hexahydro-9-amino-
mfcd00618424
VU0254176-6
1h-cyclopenta[b]quinolin-9-amine, 2,3,5,6,7,8-hexahydro-
2,3,5,6,7,8-hexahydro-1h-cyclopenta[b]quinoline-9-amine
9-amino-2,3,5,6,7,8-hexahydro-1h-cyclopenta[b]-quinoline
DB13668
AS-37850
Q15409425
BRD-K66896231-001-06-5
nik(c)\\247
CS-0071577
HY-W027553
EN300-40535
Z56766574

Research Excerpts

Actions

ExcerptReferenceRelevance
"Amiridine was found to produce a beneficial effect both at the initial and marked stages of the disease."( [Effectiveness of amiridin in senile dementia of the Alzheimer type].
Bukatina, EE; Grigor'eva, IV; Sokol'nik, EI, 1991
)
1

Dosage Studied

ExcerptRelevanceReference
" The dose-response curves for NIK-247 and tacrine were biphasic bell-shaped."( Effects of NIK-247 on CO-induced impairment of passive avoidance in mice.
Kameyama, T; Kinbara, K; Nabeshima, T; Yoshida, S, 1992
)
0.28
" The drug was prescribed in increasing dosages from 10 to 40 mg during 6 months (a dosage of 40 mg was administered from the 4th week of the treatment)."( [Neuromidin in the treatment of vascular cognitive disorders].
Golovkova, MS; Iakhno, NN; Lifshits, MIu; Zakharov, VV, 2007
)
0.34
" Thirty patients of the main group received neyromidin in dosage 80 mg/day during 3 months; 10 patients of the comparison group matched by age, sex and severity of cognitive disorders did not receive the drug."( [Neuromidin in mixed vascular and Alzheimer's dementia].
Damulin, IV; Lokshina, AB; Stepkina, DA, 2011
)
0.37
" Patients of the first group (n=25) were treated with the general drugs (vasoactive and nootropic preparations, vitamins) as well as with neyromidin in dosage of 15 mg intramuscularly 1 time a day during 10 days."( [The сomparative analysis of neyromidin and cerebrolysin effects on neurodynamic processes during craniocerebral injury].
Iurin, AA; Samartsev, IN; Shapkova, EIu; Zhivolupov, SA, 2011
)
0.37
" Twenty-five patients received basic therapy and 25 patients were treated with axamon as an add-on drug in dosage of 20 mg 3 times a day during 12 weeks."( [Treatment of patients with movement and cognitive disorders in the residual period of stroke].
Agafonov, BV; Dadasheva, MN; Karavashkina, EA; Podrezova, LA; Shevtsova, NN; Smirnova, LA; Vishniakova, TI, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aminoquinolineAny member of the class of quinolines in which the quinoline skeleton is substituted by one or more amino or substituted-amino groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency89.12510.707936.904389.1251AID504333
mitogen-activated protein kinase 1Homo sapiens (human)Potency19.95260.039816.784239.8107AID1454
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AcetylcholinesteraseElectrophorus electricus (electric eel)IC50 (µMol)0.17000.00000.94539.9400AID1240487
CholinesteraseEquus caballus (horse)IC50 (µMol)0.07000.00002.22149.4000AID1240488
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1240487Inhibition of Electrophorus electricus AChE pre-incubated for 5 mins before acetylthiocholine iodide substrate addition by Ellman's method2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Discovery of new acetylcholinesterase inhibitors with small core structures through shape-based virtual screening.
AID1240488Inhibition of equine serum BChE pre-incubated for 5 mins before butyrylthiocholineiodide substrate addition by Ellman's method2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Discovery of new acetylcholinesterase inhibitors with small core structures through shape-based virtual screening.
AID1240492Inhibition of equine serum BChE at 10 uM pre-incubated for 5 mins before butyrylthiocholineiodide substrate addition by Ellman's method2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Discovery of new acetylcholinesterase inhibitors with small core structures through shape-based virtual screening.
AID1240491Inhibition of Electrophorus electricus AChE at 10 uM pre-incubated for 5 mins before acetylthiocholine iodide substrate addition by Ellman's method2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Discovery of new acetylcholinesterase inhibitors with small core structures through shape-based virtual screening.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (99)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (5.05)18.7374
1990's41 (41.41)18.2507
2000's10 (10.10)29.6817
2010's37 (37.37)24.3611
2020's6 (6.06)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.76 (24.57)
Research Supply Index4.93 (2.92)
Research Growth Index5.39 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials23 (20.18%)5.53%
Reviews3 (2.63%)6.00%
Case Studies3 (2.63%)4.05%
Observational0 (0.00%)0.25%
Other85 (74.56%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]